No Data
No Data
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Avidity Biosciences Files Automatic Mixed Shelf
Alpine Immune Sciences Q1 EPS $(0.28) Beats $(0.41) Estimate, Sales $7.03M Beat $3.52M Estimate
Alpine Immune Sciences (NASDAQ:ALPN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.41) by 31.71 percent. This is unchanged from the same period last y
Crinetics Pharmaceuticals To Present Advancements From Atumelnant And Paltusotine Development Programs At ENDO 2024 June 1-4, 2024
Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing's Syndrome TrialData from Phase 3 P
Unveiling 5 Analyst Insights On IDEAYA Biosciences
In the preceding three months, 5 analysts have released ratings for IDEAYA Biosciences (NASDAQ:IDYA), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates t
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $80 to $79.
104983267 : logical analysis, positive yet cautious.